First Manhattan’s Tandem Diabetes Care TNDM Stock Holding History

First Manhattan’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,000	Closed	-$236K	–	1651
2022 Q2	$236K	Hold	4,000	–	–	﹤0.01%	684
2022 Q1	$465K	Hold	4,000	–	–	﹤0.01%	592
2021 Q4	$602K	Hold	4,000	–	–	﹤0.01%	536
2021 Q3	$477K	Hold	4,000	–	–	﹤0.01%	574
2021 Q2	$389K	Hold	4,000	–	–	﹤0.01%	606
2021 Q1	$353K	Hold	4,000	–	–	﹤0.01%	599
2020 Q4	$382K	Hold	4,000	–	–	﹤0.01%	560
2020 Q3	$454K	Hold	4,000	–	–	﹤0.01%	505
2020 Q2	$395K	Sell	4,000 -4,000	-50%	-$319K	﹤0.01%	531
2020 Q1	$514K	Hold	8,000	–	–	﹤0.01%	461
2019 Q4	$476K	Sell	8,000 -840	-10%	-$51.8K	﹤0.01%	534
2019 Q3	$521K	Hold	8,840	–	–	﹤0.01%	516
2019 Q2	$570K	Sell	8,840 -1,160	-12%	-$74.9K	﹤0.01%	529
2019 Q1	$635K	Hold	10,000	–	–	﹤0.01%	516
2018 Q4	$379K	Hold	10,000	–	–	﹤0.01%	590
2018 Q3	$428K	Sell	10,000 -5,300	-35%	-$185K	﹤0.01%	607
2018 Q2	$336K	Buy	+15,300	New	+$188K	﹤0.01%	610

Other funds holding TNDM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

First Manhattan's TNDM Position: Q3 2022 in Review

First Manhattan sold out of Tandem Diabetes Care (TNDM) in Q3 2022, closing a stake of 4,000 shares — an estimated $236K sold.

First Manhattan first reported a position in TNDM in Q2 2018 and held it in 17 quarters. The position peaked at $635K in Q1 2019. 299 funds tracked by Wall St. Rank hold TNDM as of Q3 2022.

First Manhattan reported no remaining Tandem Diabetes Care position as of Q3 2022 after selling out during the quarter.
First Manhattan sold 4,000 Tandem Diabetes Care shares in Q3 2022, an estimated $236K.
First Manhattan first reported a position in Tandem Diabetes Care in Q2 2018 and held it in 17 quarters.
First Manhattan's Tandem Diabetes Care position peaked at $635K in Q1 2019.
299 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2022.

Based on First Manhattan's 13F filing for Q3 2022, filed 14 Nov 2022.